Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors

Annals of the Rheumatic Diseases

Volumn 72, Issue 9, 2013, Pages 1461-1468

  Genovese, Mark C ^a   Fleischmann, Roy M ^b   Greenwald, Maria ^c   Satterwhite, Julie ^d   Veenhuizen, Melissa ^d   Xie, Li ^d   Berclaz, Pierre Yves ^d   Myers, Stephen ^d   Benichou, Olivier ^d  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c Desert Medical Advances   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; METHOTREXATE; PLACEBO; PREDNISONE; TABALUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; AMERICAN COLLEGE OF RHEUMATOLOGY; ANEMIA; ARTICLE; B LYMPHOCYTE; BURSITIS; CELL MATURATION; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HERPES ZOSTER; HUMAN; HUMAN CELL; HYPERTENSION; HYPOKALEMIA; INFECTION; INTERVERTEBRAL DISK HERNIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; OPPORTUNISTIC INFECTION; PAPULAR RASH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

AUTOIMMUNE DISEASES; METHOTREXATE; RHEUMATOID ARTHRITIS; TNF-ALPHA; TREATMENT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-CELL ACTIVATING FACTOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HUMANS; INJECTIONS, INTRAVENOUS; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84881480292     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202775     Document Type: Article

References (27)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46.
2. Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biolgocis for rheumatoid arthritis: a Cochrane review. CMAJ 2009;181:787-96.
3. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
4. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biological: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
5. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005;353:1114-23. (Pubitemid 41317434)
6. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III, trial. Lancet 2009;374:210-21.
7. Schneider P, Mackay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-56. (Pubitemid 29272691)
8. Melchers F. Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease. Ann Rheum Dis 2003;62(Suppl 2):ii25-7.
9. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009;119:1066-73.
10. Davidson A. Targeting BAFF in autoimmunity. Curr Opin Immunol 2010;22:732-9.
11. Ohata J, Zvaifler NJ, Nishio M, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005;174:864-70. (Pubitemid 40094281)
12. Bosello S, Youinou P, Daridon C, et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 2008;35:1256-64. (Pubitemid 352000768)
13. Kikly K, Manetta J, Smith H, et al. Characterization of LY2127399, a neutralizing antibody for BAFF (abstract). Arthritis Rheum 2009;60(Suppl 10):693.
14. Genovese MC, Mociran E, Biagini M, et al. Phase 2 study of safety and efficacy of a novel anti-BAFF monoclonal antibody, in patients with RA treated with methotrexate (MTX) (abstract). Arthritis Rheum 2009;60(Suppl 10):1923.
15. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
16. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
17. Van Gestel AM, Prevoo MLL, Van'T Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996;39:34-40. (Pubitemid 126575924)
18. Keystone EC, van der Heijde D, Smolen J, et al. Open-label treatment effect in patients who withdrew from double-blind treatment with certolizumab pegol: substantial improvement in patients receiving active treatment who did not respond in the double-blind phase. Ann Rheum Dis 2009;68:236.
19. Shaw M, Del Giudice J, Trapp R, et al. The safety, pharmacokinetics, and pharmacodynamic effects of repeated doses of BR3-Fc in patients with rheumatoid arthritis. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; November 6-11, 2007; Boston, Massachusetts. (Abstract #1432)
20. Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single-and repeated-dose study. Arthritis Rheum 2008;58:61-72.
21. Stohl W, Chatham W, Weisman M, et al. Belimumab, a novel fully human monoclonal antibody to B-lymphocyte stimulator (BLys), selectively modulates B-cell subpopulations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population (abstract). In: Program and Abstracts of the American College of Rheumatology (ACR) 69th Annual Meeting; 2005 Nov 12-17; San Diego, CA: Abstract 1160.
22. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum 2006;54:1390-400.
23. Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum 2008;58:2652-1.
24. McKay J, Chwalinska-Sadowska H, Boling E, et al. Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population. Arthritis Rheum 2005;52:S710.
25. Genovese MC, Filipowicz-Sosnowska A, Merrill J, et al. Differential responsiveness of belimumab (BmAb) in combination with standard of care therapy in RF+, TNFa inhibitor and MTX partial responder subgroups with moderate-severe rheumatoid arthritis (abstract). Arthritis Rheum 2005;52:S1989.
26. Genovese MC, Kinnman N, de La BG, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011;63:1793-803.
27. van Vollenhoven RF, Kinnman N, Vincent E, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011;63:1782-92.